A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy

Andrea Gallina, Marco Bianchi, Giorgio Gandaglia, Vito Cucchiara, Nazareno Suardi, Francesco Montorsi, Alberto Briganti

Research output: Contribution to journalArticle

Abstract

A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. Patient summary Among patients treated with radical prostatectomy, phosphodiesterase type 5 inhibitor use was not associated with an increased risk of biochemical recurrence, regardless of the therapeutic regimen used.

Original languageEnglish
Pages (from-to)750-753
Number of pages4
JournalEuropean Urology
Volume68
Issue number5
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Phosphodiesterase 5 Inhibitors
Prostatectomy
Recurrence
Prostatic Neoplasms
Appointments and Schedules
Proportional Hazards Models
Therapeutics
Rehabilitation

Keywords

  • Biochemical recurrence
  • Phosphodiesterase type 5 inhibitors
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy. / Gallina, Andrea; Bianchi, Marco; Gandaglia, Giorgio; Cucchiara, Vito; Suardi, Nazareno; Montorsi, Francesco; Briganti, Alberto.

In: European Urology, Vol. 68, No. 5, 01.11.2015, p. 750-753.

Research output: Contribution to journalArticle

@article{354f8f9201d24e0693b36e234efd2892,
title = "A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy",
abstract = "A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1{\%}) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. Patient summary Among patients treated with radical prostatectomy, phosphodiesterase type 5 inhibitor use was not associated with an increased risk of biochemical recurrence, regardless of the therapeutic regimen used.",
keywords = "Biochemical recurrence, Phosphodiesterase type 5 inhibitors, Prostate cancer, Radical prostatectomy",
author = "Andrea Gallina and Marco Bianchi and Giorgio Gandaglia and Vito Cucchiara and Nazareno Suardi and Francesco Montorsi and Alberto Briganti",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.eururo.2015.02.002",
language = "English",
volume = "68",
pages = "750--753",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy

AU - Gallina, Andrea

AU - Bianchi, Marco

AU - Gandaglia, Giorgio

AU - Cucchiara, Vito

AU - Suardi, Nazareno

AU - Montorsi, Francesco

AU - Briganti, Alberto

PY - 2015/11/1

Y1 - 2015/11/1

N2 - A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. Patient summary Among patients treated with radical prostatectomy, phosphodiesterase type 5 inhibitor use was not associated with an increased risk of biochemical recurrence, regardless of the therapeutic regimen used.

AB - A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. Patient summary Among patients treated with radical prostatectomy, phosphodiesterase type 5 inhibitor use was not associated with an increased risk of biochemical recurrence, regardless of the therapeutic regimen used.

KW - Biochemical recurrence

KW - Phosphodiesterase type 5 inhibitors

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84942983100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942983100&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2015.02.002

DO - 10.1016/j.eururo.2015.02.002

M3 - Article

C2 - 25700565

AN - SCOPUS:84942983100

VL - 68

SP - 750

EP - 753

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -